Company Interview / Compumedics' China milestone

Key Points:

Compumedics (ASX:CMP) secures nearly $5 million MEG order with Beijing Normal University Advanced MEG system targets disorders like autism, epilepsy, and Parkinson’s FDA approval supports US market entry with major expansion planned for 2026 Orion LifeSpan MEG system offers versatility for both children and adults

Compumedics (ASX:CMP) has secured a major neuroimaging order from Beijing Normal University, valued at almost $5 million. David Burton outlines that the deal involves the supply of a magnetoencephalography (MEG) brain scanning system, which leverages superconducting quantum interference device (SQUID) technology to detect subtle electrical activity in the brain. This advanced system is positioned as a significant step in diagnosing and studying neurofunctional disorders such as autism, epilepsy, and Parkinson’s disease. Burton states that this is the fifth such order in a commercial rollout totalling $25 million, representing nearly half of Compumedics’ global revenues in recent years.

Burton frames this contract as a milestone, not only due to its size but also due to its prestigious customer. He highlights that China is currently the fastest-growing market for this technology and points to the US as the largest. Compumedics has already received FDA approval, paving the way for further orders and expansion into the US market in 2026. Burton expects ongoing scaling, with the company currently processing two to three orders annually and a strong pipeline outlook.

The latest generation Orion LifeSpan MEG, according to Burton, provides unique features such as accommodating both children and adults in one system. With the market potential estimated at 10% of the global MRI market, Burton suggests a possible $14 billion addressable market for Compumedics.